Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR. However, its clinical efficacy is severely compromised by the emergence of resistance primarily due to acquir...
Shranjeno v:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2015-12-01
|
| Serija: | Journal of Pharmacological Sciences |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S1347861315002194 |
| Oznake: |
Brez oznak, prvi označite!
|